{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:55:57Z","timestamp":1792119357189,"version":"4.4.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-04188-0","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T03:54:45Z","timestamp":1768794885000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Recent advances in molecular classification and multimodal treatment of intrahepatic cholangiocarcinoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Fazal","family":"Saboor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"issue":"1","key":"4188_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21332.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"4188_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.21037\/hbsn.2018.03.16","volume":"7","author":"EW Beal","year":"2018","unstructured":"Beal EW, Tumin D, Moris D, Zhang XF, Chakedis J, Dilhoff M, et al. Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2018;7(4):270\u20136. https:\/\/doi.org\/10.21037\/hbsn.2018.03.16.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"11","key":"4188_CR3","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1002\/cncr.32803","volume":"126","author":"AA Florio","year":"2020","unstructured":"Florio AA, Ferlay J, Znaor A, Ruggieri D, Alvarez CS, Laversanne M, et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer. 2020;126(11):2666\u201378. https:\/\/doi.org\/10.1002\/cncr.32803.","journal-title":"Cancer"},{"issue":"10","key":"4188_CR4","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.cgh.2007.05.020","volume":"5","author":"TM Welzel","year":"2007","unstructured":"Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the united states: a population-based case-control study. Clin Gastroenterol Hepatol. 2007;5(10):1221\u20138. https:\/\/doi.org\/10.1016\/j.cgh.2007.05.020.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"4188_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12885-019-5391-0","volume":"19","author":"PL Labib","year":"2019","unstructured":"Labib PL, Goodchild G, Pereira SP. Molecular pathogenesis of cholangiocarcinoma. BMC Cancer. 2019;19(1):185. https:\/\/doi.org\/10.1186\/s12885-019-5391-0.","journal-title":"BMC Cancer"},{"issue":"11","key":"4188_CR6","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Final overall survival efficacy results of Ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021;7(11):1669\u201377. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3836.","journal-title":"JAMA Oncol"},{"key":"4188_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev-med-042921-024707","volume":"74","author":"A Vogel","year":"2023","unstructured":"Vogel A, Segatto O, Stenzinger A, Saborowski A. FGFR2 Inhibition in cholangiocarcinoma. Annu Rev Med. 2023;74:293\u2013306. https:\/\/doi.org\/10.1146\/annurev-med-042921-024707.","journal-title":"Annu Rev Med"},{"issue":"1","key":"4188_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/SLA.0b013e318176c4d3","volume":"248","author":"I Endo","year":"2008","unstructured":"Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84\u201396. https:\/\/doi.org\/10.1097\/SLA.0b013e318176c4d3.","journal-title":"Ann Surg"},{"issue":"4","key":"4188_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.soc.2019.06.002","volume":"28","author":"R El-Diwany","year":"2019","unstructured":"El-Diwany R, Pawlik TM, Ejaz A. Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am. 2019;28(4):587\u201399. https:\/\/doi.org\/10.1016\/j.soc.2019.06.002.","journal-title":"Surg Oncol Clin N Am"},{"issue":"5","key":"4188_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","volume":"13","author":"JM Banales","year":"2016","unstructured":"Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261\u201380. https:\/\/doi.org\/10.1038\/nrgastro.2016.51.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"4188_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.21037\/hbsn.2016.11.04","volume":"6","author":"S Vijgen","year":"2017","unstructured":"Vijgen S, Terris B, Rubbia-Brandt L. Pathology of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6(1):22\u201334. https:\/\/doi.org\/10.21037\/hbsn.2016.11.04.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"8","key":"4188_CR12","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1097\/PAS.0000000000000670","volume":"40","author":"A Hayashi","year":"2016","unstructured":"Hayashi A, Misumi K, Shibahara J, Arita J, Sakamoto Y, Hasegawa K, et al. Distinct clinicopathologic and genetic features of 2 histologic subtypes of intrahepatic cholangiocarcinoma. Am J Surg Pathol. 2016;40(8):1021\u201330. https:\/\/doi.org\/10.1097\/PAS.0000000000000670.","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"4188_CR13","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","volume":"7","author":"JW Valle","year":"2017","unstructured":"Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7(9):943\u201362. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0245.","journal-title":"Cancer Discov"},{"issue":"4","key":"4188_CR14","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1097\/XCS.0000000000000948","volume":"238","author":"J Purchla","year":"2024","unstructured":"Purchla J, Ghabi EM, Burns WR, Lafaro KJ, Burkhart RA, Cameron JL, et al. Exploring the clinical use of molecular profiling of intrahepatic cholangiocarcinoma in a comprehensive multidisciplinary clinic. J Am Coll Surg. 2024;238(4):532\u201340. https:\/\/doi.org\/10.1097\/XCS.0000000000000948.","journal-title":"J Am Coll Surg"},{"issue":"9","key":"4188_CR15","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41416-022-01932-1","volume":"127","author":"A Tomczak","year":"2022","unstructured":"Tomczak A, Springfeld C, Dill MT, Chang DH, Kazdal D, Wagner U, et al. Precision oncology for intrahepatic cholangiocarcinoma in clinical practice. Br J Cancer. 2022;127(9):1701\u20138. https:\/\/doi.org\/10.1038\/s41416-022-01932-1.","journal-title":"Br J Cancer"},{"issue":"8","key":"4188_CR16","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/modpathol.2013.241","volume":"27","author":"JY Liau","year":"2014","unstructured":"Liau JY, Tsai JH, Yuan RH, Chang CN, Lee HJ, Jeng YM. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. Mod Pathol. 2014;27(8):1163\u201373. https:\/\/doi.org\/10.1038\/modpathol.2013.241.","journal-title":"Mod Pathol"},{"issue":"4","key":"4188_CR17","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1053\/j.gastro.2013.01.001","volume":"144","author":"D Sia","year":"2013","unstructured":"Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013;144(4):829\u201340. https:\/\/doi.org\/10.1053\/j.gastro.2013.01.001.","journal-title":"Gastroenterology"},{"issue":"1","key":"4188_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","volume":"40","author":"L Dong","year":"2022","unstructured":"Dong L, Lu D, Chen R, Lin Y, Zhu H, Zhang Z, et al. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. Cancer Cell. 2022;40(1):70\u2013e8715. https:\/\/doi.org\/10.1016\/j.ccell.2021.12.006.","journal-title":"Cancer Cell"},{"issue":"1","key":"4188_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bbamcr.2014.10.003","volume":"1853","author":"C Fiorini","year":"2015","unstructured":"Fiorini C, Cordani M, Padroni C, Blandino G, Di Agostino S, Donadelli M. Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine. Biochim Biophys Acta. 2015;1853(1):89\u2013100. https:\/\/doi.org\/10.1016\/j.bbamcr.2014.10.003.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"4188_CR20","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/gutjnl-2021-326514","volume":"72","author":"MA Martin-Serrano","year":"2023","unstructured":"Martin-Serrano MA, Kepecs B, Torres-Martin M, Bramel ER, Haber PK, Merritt E, et al. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut. 2023;72(4):736\u201348. https:\/\/doi.org\/10.1136\/gutjnl-2021-326514.","journal-title":"Gut"},{"issue":"3","key":"4188_CR21","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/hep.31092","volume":"72","author":"S Job","year":"2020","unstructured":"Job S, Rapoud D, Dos Santos A, Gonzalez P, Desterke C, Pascal G, et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma. Hepatology. 2020;72(3):965\u201381. https:\/\/doi.org\/10.1002\/hep.31092.","journal-title":"Hepatology"},{"key":"4188_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","volume":"161","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Ferlay J, de Martel C, Georges D, Ibrahim AS, Zheng R, et al. Global, regional and National burden of primary liver cancer by subtype. Eur J Cancer. 2022;161:108\u201318. https:\/\/doi.org\/10.1016\/j.ejca.2021.11.023.","journal-title":"Eur J Cancer"},{"issue":"19","key":"4188_CR23","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.3748\/wjg.v17.i19.2372","volume":"17","author":"WM Cong","year":"2011","unstructured":"Cong WM, Dong H, Tan L, Sun XX, Wu MC. Surgicopathological classification of hepatic space-occupying lesions: a single-center experience with literature review. World J Gastroenterol. 2011;17(19):2372\u20138. https:\/\/doi.org\/10.3748\/wjg.v17.i19.2372.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"4188_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.21037\/hbsn-21-75","volume":"12","author":"L An","year":"2023","unstructured":"An L, Zheng R, Zhang S, Chen R, Wang S, Sun K, et al. Hepatocellular carcinoma and intrahepatic cholangiocarcinoma incidence between 2006 and 2015 in china: estimates based on data from 188 population-based cancer registries. Hepatobiliary Surg Nutr. 2023;12(1):45\u201355. https:\/\/doi.org\/10.21037\/hbsn-21-75.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"2","key":"4188_CR25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3322\/caac.21759","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;73(2):198\u2013222. https:\/\/doi.org\/10.3322\/caac.21759.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"4188_CR26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000534443","volume":"13","author":"N Nishida","year":"2024","unstructured":"Nishida N, Kudo M. Genetic\/Epigenetic alteration and tumor immune microenvironment in intrahepatic cholangiocarcinoma: transforming the immune microenvironment with Molecular-Targeted agents. Liver Cancer. 2024;13(2):136\u201349. https:\/\/doi.org\/10.1159\/000534443.","journal-title":"Liver Cancer"},{"key":"4188_CR27","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1038\/ncomms6696","volume":"5","author":"S Zou","year":"2014","unstructured":"Zou S, Li J, Zhou H, Frech C, Jiang X, Chu JS, et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun. 2014;5:5696. https:\/\/doi.org\/10.1038\/ncomms6696.","journal-title":"Nat Commun"},{"issue":"19","key":"4188_CR28","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1097\/CM9.0000000000003258","volume":"137","author":"X Wang","year":"2024","unstructured":"Wang X, Bai Y, Chai N, Li Y, Linghu E, Wang L, et al. Chinese National clinical practice guideline on diagnosis and treatment of biliary tract cancers. Chin Med J (Engl). 2024;137(19):2272\u201393. https:\/\/doi.org\/10.1097\/CM9.0000000000003258.","journal-title":"Chin Med J (Engl)"},{"key":"4188_CR29","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Biliary Tract Cancers (Version 2.2025): National Comprehensive Cancer Network. 2025 [cited December 16, 2025]. Available from: https:\/\/www.nccn.org"},{"issue":"9","key":"4188_CR30","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.annonc.2021.04.012","volume":"32","author":"TS Bekaii-Saab","year":"2021","unstructured":"Bekaii-Saab TS, Bridgewater J, Normanno N. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Ann Oncol. 2021;32(9):1111\u201326. https:\/\/doi.org\/10.1016\/j.annonc.2021.04.012.","journal-title":"Ann Oncol"},{"issue":"10","key":"4188_CR31","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.7150\/thno.56539","volume":"11","author":"J Lin","year":"2021","unstructured":"Lin J, Cao Y, Yang X, Li G, Shi Y, Wang D, et al. Mutational spectrum and precision oncology for biliary tract carcinoma. Theranostics. 2021;11(10):4585\u201398. https:\/\/doi.org\/10.7150\/thno.56539.","journal-title":"Theranostics"},{"issue":"Suppl 1","key":"4188_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/liv.14093","volume":"39","author":"T Kendall","year":"2019","unstructured":"Kendall T, Verheij J, Gaudio E, Evert M, Guido M, Goeppert B, et al. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):7\u201318. https:\/\/doi.org\/10.1111\/liv.14093.","journal-title":"Liver Int"},{"issue":"17","key":"4188_CR33","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","volume":"24","author":"MA Lowery","year":"2018","unstructured":"Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24(17):4154\u201361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0078.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4188_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","volume":"16","author":"M Katoh","year":"2019","unstructured":"Katoh M. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat Rev Clin Oncol. 2019;16(2):105\u201322. https:\/\/doi.org\/10.1038\/s41571-018-0115-y.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"4188_CR35","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/s41416-022-01908-1","volume":"127","author":"O Neumann","year":"2022","unstructured":"Neumann O, Burn TC, Allgauer M, Ball M, Kirchner M, Albrecht T, et al. Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing. Br J Cancer. 2022;127(8):1540\u20139. https:\/\/doi.org\/10.1038\/s41416-022-01908-1.","journal-title":"Br J Cancer"},{"issue":"6","key":"4188_CR36","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.14218\/JCTH.2022.00060S","volume":"11","author":"Y Zou","year":"2023","unstructured":"Zou Y, Zhu K, Pang Y, Han J, Zhang X, Jiang Z, et al. Molecular detection of FGFR2 rearrangements in resected intrahepatic cholangiocarcinomas: FISH could be an ideal method in patients with histological small duct subtype. J Clin Transl Hepatol. 2023;11(6):1355\u201367. https:\/\/doi.org\/10.14218\/JCTH.2022.00060S.","journal-title":"J Clin Transl Hepatol"},{"key":"4188_CR37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.humpath.2017.12.028","volume":"76","author":"XH Pu","year":"2018","unstructured":"Pu XH, Ye Q, Yang J, Wu HY, Ding XW, Shi J, et al. Low-level clonal FGFR2 amplification defines a unique molecular subtype of intrahepatic cholangiocarcinoma in a Chinese population. Hum Pathol. 2018;76:100\u20139. https:\/\/doi.org\/10.1016\/j.humpath.2017.12.028.","journal-title":"Hum Pathol"},{"issue":"5","key":"4188_CR38","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671\u201384. https:\/\/doi.org\/10.1016\/S1470-2045(20)30109-1.","journal-title":"Lancet Oncol"},{"issue":"3","key":"4188_CR39","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, et al. Futibatinib for FGFR2-Rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388(3):228\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2206834.","journal-title":"N Engl J Med"},{"issue":"6","key":"4188_CR40","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796\u2013807. https:\/\/doi.org\/10.1016\/S1470-2045(20)30157-1.","journal-title":"Lancet Oncol"},{"issue":"3","key":"4188_CR41","doi-asserted-by":"publisher","first-page":"e231476","DOI":"10.1001\/jamanetworkopen.2023.1476","volume":"6","author":"HY Xin","year":"2023","unstructured":"Xin HY, Sun RQ, Zou JX, Wang PC, Wang JY, Ye YH, et al. Association of BRAF variants with disease Characteristics, Prognosis, and targeted therapy response in intrahepatic cholangiocarcinoma. JAMA Netw Open. 2023;6(3):e231476. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.1476.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"4188_CR42","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","volume":"9","author":"R Yaeger","year":"2019","unstructured":"Yaeger R, Corcoran RB. Targeting alterations in the RAF-MEK pathway. Cancer Discov. 2019;9(3):329\u201341. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1321.","journal-title":"Cancer Discov"},{"issue":"7","key":"4188_CR43","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/modpathol.2013.206","volume":"27","author":"B Goeppert","year":"2014","unstructured":"Goeppert B, Frauenschuh L, Renner M, Roessler S, Stenzinger A, Klauschen F, et al. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. Mod Pathol. 2014;27(7):1028\u201334. https:\/\/doi.org\/10.1038\/modpathol.2013.206.","journal-title":"Mod Pathol"},{"key":"4188_CR44","doi-asserted-by":"publisher","unstructured":"Ayasun R, Ozer M, Sahin I. The role of HER2 status in the biliary tract cancers. Cancers (Basel). 2023;15(9). https:\/\/doi.org\/10.3390\/cancers15092628.","DOI":"10.3390\/cancers15092628"},{"key":"4188_CR45","doi-asserted-by":"publisher","unstructured":"Cao J, Hu J, Liu S, Meric-Bernstam F, Abdel-Wahab R, Xu J, et al. Intrahepatic cholangiocarcinoma: genomic heterogeneity between Eastern and Western patients. JCO Precis Oncol. 2020;4. https:\/\/doi.org\/10.1200\/PO.18.00414.","DOI":"10.1200\/PO.18.00414"},{"issue":"1","key":"4188_CR46","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41467-023-36399-y","volume":"14","author":"JJ Harding","year":"2023","unstructured":"Harding JJ, Piha-Paul SA, Shah RH, Murphy JJ, Cleary JM, Shapiro GI, et al. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. Nat Commun. 2023;14(1):630. https:\/\/doi.org\/10.1038\/s41467-023-36399-y.","journal-title":"Nat Commun"},{"issue":"9","key":"4188_CR47","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","volume":"22","author":"M Javle","year":"2021","unstructured":"Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021;22(9):1290\u2013300. https:\/\/doi.org\/10.1016\/S1470-2045(21)00336-3.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4188_CR48","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, Gonzalez-Martin A, et al. Efficacy and safety of trastuzumab Deruxtecan in patients with HER2-Expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42(1):47\u201358. https:\/\/doi.org\/10.1200\/JCO.23.02005.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4188_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1158\/2159-8290.CD-14-0765","volume":"5","author":"A Vaishnavi","year":"2015","unstructured":"Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5(1):25\u201334. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0765.","journal-title":"Cancer Discov"},{"issue":"1","key":"4188_CR50","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41698-023-00427-3","volume":"7","author":"Y Xu","year":"2023","unstructured":"Xu Y, Shi X, Wang W, Zhang L, Cheung S, Rudolph M, et al. Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China. NPJ Precis Oncol. 2023;7(1):75. https:\/\/doi.org\/10.1038\/s41698-023-00427-3.","journal-title":"NPJ Precis Oncol"},{"issue":"3","key":"4188_CR51","doi-asserted-by":"publisher","first-page":"199","DOI":"10.32074\/1591-951X-787","volume":"114","author":"A Marchetti","year":"2022","unstructured":"Marchetti A, Ferro B, Pasciuto MP, Zampacorta C, Buttitta F, D\u2019Angelo E. NTRK gene fusions in solid tumors: agnostic relevance, prevalence and diagnostic strategies. Pathologica. 2022;114(3):199\u2013216. https:\/\/doi.org\/10.32074\/1591-951X-787.","journal-title":"Pathologica"},{"issue":"21","key":"4188_CR52","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1111\/1759-7714.14644","volume":"13","author":"C Xu","year":"2022","unstructured":"Xu C, Si L, Wang W, Li Z, Song Z, Wang Q, et al. Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China. Thorac Cancer. 2022;13(21):3084\u201397. https:\/\/doi.org\/10.1111\/1759-7714.14644.","journal-title":"Thorac Cancer"},{"issue":"7","key":"4188_CR53","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/his.14884","volume":"82","author":"M Haberecker","year":"2023","unstructured":"Haberecker M, Topfer A, Melega F, Moch H, Pauli C. A systematic comparison of pan-Trk immunohistochemistry assays among multiple cancer types. Histopathology. 2023;82(7):1003\u201312. https:\/\/doi.org\/10.1111\/his.14884.","journal-title":"Histopathology"},{"key":"4188_CR54","doi-asserted-by":"publisher","first-page":"101911","DOI":"10.1016\/j.ctrv.2019.101911","volume":"81","author":"AY Li","year":"2019","unstructured":"Li AY, McCusker MG, Russo A, Scilla KA, Gittens A, Arensmeyer K, et al. RET fusions in solid tumors. Cancer Treat Rev. 2019;81:101911. https:\/\/doi.org\/10.1016\/j.ctrv.2019.101911.","journal-title":"Cancer Treat Rev"},{"issue":"18","key":"4188_CR55","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1158\/1078-0432.CCR-23-0459","volume":"29","author":"ES Duke","year":"2023","unstructured":"Duke ES, Bradford D, Marcovitz M, Amatya AK, Mishra-Kalyani PS, Nguyen E, et al. FDA approval summary: Selpercatinib for the treatment of advanced RET Fusion-Positive solid tumors. Clin Cancer Res. 2023;29(18):3573\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0459.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"4188_CR56","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","volume":"28","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Cassier PA, Siena S, Garralda E, Paz-Ares L, Garrido P, et al. Pan-cancer efficacy of Pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial. Nat Med. 2022;28(8):1640\u20135. https:\/\/doi.org\/10.1038\/s41591-022-01931-y.","journal-title":"Nat Med"},{"issue":"1","key":"4188_CR57","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jamasurg.2021.5679","volume":"157","author":"SL Zhou","year":"2022","unstructured":"Zhou SL, Xin HY, Sun RQ, Zhou ZJ, Hu ZQ, Luo CB, et al. Association of KRAS variant subtypes with survival and recurrence in patients with surgically treated intrahepatic cholangiocarcinoma. JAMA Surg. 2022;157(1):59\u201365. https:\/\/doi.org\/10.1001\/jamasurg.2021.5679.","journal-title":"JAMA Surg"},{"issue":"25","key":"4188_CR58","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, et al. Acquired resistance to KRAS(G12C) Inhibition in cancer. N Engl J Med. 2021;384(25):2382\u201393. https:\/\/doi.org\/10.1056\/NEJMoa2105281.","journal-title":"N Engl J Med"},{"issue":"1","key":"4188_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite Instability\/Mismatch Repair-Deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1\u201310. https:\/\/doi.org\/10.1200\/JCO.19.02105.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4188_CR60","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12916-024-03257-7","volume":"22","author":"X Yang","year":"2024","unstructured":"Yang X, Lian B, Zhang N, Long J, Li Y, Xue J, et al. Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma. BMC Med. 2024;22(1):42. https:\/\/doi.org\/10.1186\/s12916-024-03257-7.","journal-title":"BMC Med"},{"key":"4188_CR61","doi-asserted-by":"publisher","first-page":"153874","DOI":"10.1016\/j.prp.2022.153874","volume":"233","author":"SY Kang","year":"2022","unstructured":"Kang SY, Kim DG, Ahn S, Ha SY, Jang KT, Kim KM. Comparative analysis of microsatellite instability by next-generation sequencing, MSI PCR and MMR immunohistochemistry in 1942 solid cancers. Pathol Res Pract. 2022;233:153874. https:\/\/doi.org\/10.1016\/j.prp.2022.153874.","journal-title":"Pathol Res Pract"},{"issue":"3","key":"4188_CR62","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.trecan.2021.11.003","volume":"8","author":"M Nagasaka","year":"2022","unstructured":"Nagasaka M, Ou SI. NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis. Trends Cancer. 2022;8(3):242\u201358. https:\/\/doi.org\/10.1016\/j.trecan.2021.11.003.","journal-title":"Trends Cancer"},{"issue":"16","key":"4188_CR63","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2217\/fon-2023-0824","volume":"20","author":"DW Kim","year":"2024","unstructured":"Kim DW, Schram AM, Hollebecque A, Nishino K, Macarulla T, Rha SY, et al. The phase I\/II eNRGy trial: zenocutuzumab in patients with cancers harboring NRG1 gene fusions. Future Oncol. 2024;20(16):1057\u201367. https:\/\/doi.org\/10.2217\/fon-2023-0824.","journal-title":"Future Oncol"},{"issue":"1","key":"4188_CR64","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1055\/s-0044-1781457","volume":"11","author":"C Xu","year":"2024","unstructured":"Xu C, Wang Q, Wang D, Wang W, Fang W, Li Z, et al. Expert consensus on the diagnosis and treatment of NRG1\/2 gene fusion solid tumors. Glob Med Genet. 2024;11(1):86\u201399. https:\/\/doi.org\/10.1055\/s-0044-1781457.","journal-title":"Glob Med Genet"},{"issue":"12","key":"4188_CR65","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.annonc.2022.09.150","volume":"33","author":"JE Berchuck","year":"2022","unstructured":"Berchuck JE, Facchinetti F, DiToro DF, Baiev I, Majeed U, Reyes S, et al. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer. Ann Oncol. 2022;33(12):1269\u201383. https:\/\/doi.org\/10.1016\/j.annonc.2022.09.150.","journal-title":"Ann Oncol"},{"key":"4188_CR66","doi-asserted-by":"publisher","unstructured":"Lamarca A, Kapacee Z, Breeze M, Bell C, Belcher D, Staiger H, et al. Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers. J Clin Med. 2020;9(9). https:\/\/doi.org\/10.3390\/jcm9092854.","DOI":"10.3390\/jcm9092854"},{"key":"4188_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00324","volume":"3","author":"K Mody","year":"2019","unstructured":"Mody K, Kasi PM, Yang J, Surapaneni PK, Bekaii-Saab T, Ahn DH, et al. Circulating tumor DNA profiling of advanced biliary tract cancers. JCO Precis Oncol. 2019;3:1\u20139. https:\/\/doi.org\/10.1200\/PO.18.00324.","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"4188_CR68","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/archsurg.2012.1962","volume":"147","author":"D Ribero","year":"2012","unstructured":"Ribero D, Pinna AD, Guglielmi A, Ponti A, Nuzzo G, Giulini SM, et al. Surgical approach for Long-term survival of patients with intrahepatic cholangiocarcinoma: A Multi-institutional analysis of 434 patients. Arch Surg. 2012;147(12):1107\u201313. https:\/\/doi.org\/10.1001\/archsurg.2012.1962.","journal-title":"Arch Surg"},{"issue":"4","key":"4188_CR69","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.21037\/jgo-24-165","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, Alsaraf Y, Bandaru SS, Lyons S, Reap L, Ngo T, et al. Epidemiology, survival and new treatment modalities for intrahepatic cholangiocarcinoma. J Gastrointest Oncol. 2024;15(4):1777\u201388. https:\/\/doi.org\/10.21037\/jgo-24-165.","journal-title":"J Gastrointest Oncol"},{"issue":"5","key":"4188_CR70","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1097\/SLA.0b013e318236c21d","volume":"254","author":"O Farges","year":"2011","unstructured":"Farges O, Fuks D, Boleslawski E, Le Treut YP, Castaing D, Laurent A, et al. Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group. Ann Surg. 2011;254(5):824\u201329. https:\/\/doi.org\/10.1097\/SLA.0b013e318236c21d. discussion 30.","journal-title":"Ann Surg"},{"issue":"2","key":"4188_CR71","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jhep.2022.12.003","volume":"78","author":"BG Koerkamp","year":"2023","unstructured":"Koerkamp BG, Clavien PA, Polak WG. Surgical resection for intrahepatic cholangiocarcinoma - can we really improve survival by resecting more lymph nodes? J Hepatol. 2023;78(2):235\u20137. https:\/\/doi.org\/10.1016\/j.jhep.2022.12.003.","journal-title":"J Hepatol"},{"issue":"9","key":"4188_CR72","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1245\/s10434-019-07483-9","volume":"26","author":"K Sahara","year":"2019","unstructured":"Sahara K, Tsilimigras DI, Merath K, Bagante F, Guglielmi A, Aldrighetti L, et al. Therapeutic index associated with lymphadenectomy among patients with intrahepatic cholangiocarcinoma: which patients benefit the most from nodal evaluation? Ann Surg Oncol. 2019;26(9):2959\u201368. https:\/\/doi.org\/10.1245\/s10434-019-07483-9.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"4188_CR73","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.hpb.2018.12.011","volume":"21","author":"R Zhou","year":"2019","unstructured":"Zhou R, Lu D, Li W, Tan W, Zhu S, Chen X, et al. Is lymph node dissection necessary for resectable intrahepatic cholangiocarcinoma? A systematic review and meta-analysis. HPB (Oxford). 2019;21(7):784\u201392. https:\/\/doi.org\/10.1016\/j.hpb.2018.12.011.","journal-title":"HPB (Oxford)"},{"issue":"1","key":"4188_CR74","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11605-007-0335-4","volume":"12","author":"NS Becker","year":"2008","unstructured":"Becker NS, Rodriguez JA, Barshes NR, O\u2019Mahony CA, Goss JA, Aloia TA. Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg. 2008;12(1):117\u201322. https:\/\/doi.org\/10.1007\/s11605-007-0335-4.","journal-title":"J Gastrointest Surg"},{"issue":"5","key":"4188_CR75","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S2468-1253(18)30045-1","volume":"3","author":"KE Lunsford","year":"2018","unstructured":"Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-Wahab R, Gupta N, et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol. 2018;3(5):337\u201348. https:\/\/doi.org\/10.1016\/S2468-1253(18)30045-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"4188_CR76","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/hep.28744","volume":"64","author":"G Sapisochin","year":"2016","unstructured":"Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, et al. Liver transplantation for very early intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment. Hepatology. 2016;64(4):1178\u201388. https:\/\/doi.org\/10.1002\/hep.28744.","journal-title":"Hepatology"},{"issue":"2","key":"4188_CR77","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/hep.32258","volume":"75","author":"G Sapisochin","year":"2022","unstructured":"Sapisochin G, Ivanics T, Heimbach J. Liver transplantation for intrahepatic cholangiocarcinoma: ready for prime time? Hepatology. 2022;75(2):455\u201372. https:\/\/doi.org\/10.1002\/hep.32258.","journal-title":"Hepatology"},{"issue":"4","key":"4188_CR78","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.surg.2022.12.014","volume":"174","author":"L Zeng","year":"2023","unstructured":"Zeng L, He C, Li X. Prognosis for intrahepatic cholangiocarcinoma after liver transplantation by size of tumor. Surgery. 2023;174(4):1094. https:\/\/doi.org\/10.1016\/j.surg.2022.12.014.","journal-title":"Surgery"},{"issue":"3","key":"4188_CR79","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/ajt.16906","volume":"22","author":"RR McMillan","year":"2022","unstructured":"McMillan RR, Javle M, Kodali S, Saharia A, Mobley C, Heyne K, et al. Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma. Am J Transpl. 2022;22(3):823\u201332. https:\/\/doi.org\/10.1111\/ajt.16906.","journal-title":"Am J Transpl"},{"issue":"5","key":"4188_CR80","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(18)30915-X.","journal-title":"Lancet Oncol"},{"issue":"10372","key":"4188_CR81","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","volume":"401","author":"K Nakachi","year":"2023","unstructured":"Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023;401(10372):195\u2013203. https:\/\/doi.org\/10.1016\/S0140-6736(22)02038-4.","journal-title":"Lancet"},{"issue":"3","key":"4188_CR82","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/bjs.10776","volume":"105","author":"T Ebata","year":"2018","unstructured":"Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, Ohtsuka M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105(3):192\u2013202. https:\/\/doi.org\/10.1002\/bjs.10776.","journal-title":"Br J Surg"},{"issue":"8","key":"4188_CR83","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.18.00050","volume":"37","author":"J Edeline","year":"2019","unstructured":"Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A randomized phase III study. J Clin Oncol. 2019;37(8):658\u201367. https:\/\/doi.org\/10.1200\/JCO.18.00050.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4188_CR84","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Klumpen HJ, Malka D, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127\u201340. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.506.","journal-title":"Ann Oncol"},{"key":"4188_CR85","doi-asserted-by":"crossref","unstructured":"Goetze TO, Vogel A, Pratschke J, Behrend M, Reim D, Schnitzbauer AA et al. Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer: final results from the phase III AIO\/CALGP\/ACO-GAIN-Trial. J Clin Oncol. 2025;43(16_suppl):4008-. doi10.1200\/JCO.2025.43.16_suppl.4008.","DOI":"10.1200\/JCO.2025.43.16_suppl.4008"},{"issue":"1","key":"4188_CR86","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1186\/s12885-025-15203-8","volume":"25","author":"Y Liu","year":"2025","unstructured":"Liu Y, Wu C, Huang Q, Zhou Y, Tang K. Neoadjuvant chemotherapy followed by surgery versus upfront surgery for intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. BMC Cancer. 2025;25(1):1757. https:\/\/doi.org\/10.1186\/s12885-025-15203-8.","journal-title":"BMC Cancer"},{"issue":"1","key":"4188_CR87","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","volume":"6","author":"A Cercek","year":"2020","unstructured":"Cercek A, Boerner T, Tan BR, Chou JF, Gonen M, Boucher TM, et al. Assessment of hepatic arterial infusion of Floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: A phase 2 clinical trial. JAMA Oncol. 2020;6(1):60\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3718.","journal-title":"JAMA Oncol"},{"issue":"7","key":"4188_CR88","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1002\/cncr.25625","volume":"117","author":"MV Kiefer","year":"2011","unstructured":"Kiefer MV, Albert M, McNally M, Robertson M, Sun W, Fraker D, et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and Polyvinyl alcohol: a 2-center study. Cancer. 2011;117(7):1498\u2013505. https:\/\/doi.org\/10.1002\/cncr.25625.","journal-title":"Cancer"},{"issue":"3","key":"4188_CR89","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/ijc.26407","volume":"131","author":"TJ Vogl","year":"2012","unstructured":"Vogl TJ, Naguib NN, Nour-Eldin NE, Bechstein WO, Zeuzem S, Trojan J, et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: results and prognostic factors governing treatment success. Int J Cancer. 2012;131(3):733\u201340. https:\/\/doi.org\/10.1002\/ijc.26407.","journal-title":"Int J Cancer"},{"issue":"9","key":"4188_CR90","doi-asserted-by":"publisher","first-page":"5462","DOI":"10.1245\/s10434-022-11932-3","volume":"29","author":"RCG Martin 2nd","year":"2022","unstructured":"Martin RCG 2nd, Simo KA, Hansen P, Rocha F, Philips P, McMasters KM, et al. Drug-Eluting Bead, Irinotecan therapy of unresectable intrahepatic cholangiocarcinoma (DELTIC) with concomitant systemic gemcitabine and cisplatin. Ann Surg Oncol. 2022;29(9):5462\u201373. https:\/\/doi.org\/10.1245\/s10434-022-11932-3.","journal-title":"Ann Surg Oncol"},{"key":"4188_CR91","doi-asserted-by":"publisher","first-page":"940009","DOI":"10.3389\/fimmu.2022.940009","volume":"13","author":"XG Yang","year":"2022","unstructured":"Yang XG, Sun YY, Li DS, Xu GH, Huang XQ. Efficacy and safety of Drug-Eluting beads transarterial chemoembolization combining immune checkpoint inhibitors in unresectable intrahepatic cholangiocarcinoma: A propensity score matching analysis. Front Immunol. 2022;13:940009. https:\/\/doi.org\/10.3389\/fimmu.2022.940009.","journal-title":"Front Immunol"},{"issue":"5","key":"4188_CR92","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.ejso.2022.01.009","volume":"48","author":"TR Lv","year":"2022","unstructured":"Lv TR, Hu HJ, Liu F, Regmi P, Jin YW, Li FY. The effect of trans arterial chemoembolization in the management of intrahepatic cholangiocarcinoma. A systematic review and meta-analysis. Eur J Surg Oncol. 2022;48(5):956\u201366. https:\/\/doi.org\/10.1016\/j.ejso.2022.01.009.","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"4188_CR93","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s11547-024-01781-3","volume":"129","author":"N Jiang","year":"2024","unstructured":"Jiang N, Zhang Z, Yin X, Qiu H, Yan W, Hao Y, et al. Systemic chemotherapy plus transarterial chemoembolization versus systemic chemotherapy alone for unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study. Radiol Med. 2024;129(4):631\u201342. https:\/\/doi.org\/10.1007\/s11547-024-01781-3.","journal-title":"Radiol Med"},{"issue":"1","key":"4188_CR94","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","volume":"6","author":"J Edeline","year":"2020","unstructured":"Edeline J, Touchefeu Y, Guiu B, Farge O, Tougeron D, Baumgaertner I, et al. Radioembolization plus chemotherapy for First-line treatment of locally advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial. JAMA Oncol. 2020;6(1):51\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3702.","journal-title":"JAMA Oncol"},{"issue":"4","key":"4188_CR95","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2967\/jnumed.122.264598","volume":"64","author":"BM Schaarschmidt","year":"2023","unstructured":"Schaarschmidt BM, Kloeckner R, Dertnig T, Demircioglu A, Muller L, Auer TA, et al. Real-Life experience in the treatment of intrahepatic cholangiocarcinoma by (90)Y radioembolization: A multicenter retrospective study. J Nucl Med. 2023;64(4):529\u201335. https:\/\/doi.org\/10.2967\/jnumed.122.264598.","journal-title":"J Nucl Med"},{"issue":"1","key":"4188_CR96","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/HEP.0000000000000544","volume":"79","author":"J Edeline","year":"2024","unstructured":"Edeline J, Bridgewater J, Campillo-Gimenez B, Neveu E, Phelip JM, Neuzillet C, et al. Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: data from clinical trials. Hepatology. 2024;79(1):96\u2013106. https:\/\/doi.org\/10.1097\/HEP.0000000000000544.","journal-title":"Hepatology"},{"issue":"5","key":"4188_CR97","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1159\/000525489","volume":"11","author":"SL Chan","year":"2022","unstructured":"Chan SL, Chotipanich C, Choo SP, Kwang SW, Mo F, Worakitsitisatorn A, et al. Selective internal radiation therapy with Yttrium-90 resin microspheres followed by gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma: A phase 2 Single-Arm multicenter clinical trial. Liver Cancer. 2022;11(5):451\u20139. https:\/\/doi.org\/10.1159\/000525489.","journal-title":"Liver Cancer"},{"issue":"7","key":"4188_CR98","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1001\/jamasurg.2022.1298","volume":"157","author":"S Franssen","year":"2022","unstructured":"Franssen S, Soares KC, Jolissaint JS, Tsilimigras DI, Buettner S, Alexandrescu S, et al. Comparison of hepatic arterial infusion pump chemotherapy vs resection for patients with multifocal intrahepatic cholangiocarcinoma. JAMA Surg. 2022;157(7):590\u20136. https:\/\/doi.org\/10.1001\/jamasurg.2022.1298.","journal-title":"JAMA Surg"},{"issue":"1","key":"4188_CR99","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.surg.2023.01.019","volume":"174","author":"A Scott","year":"2023","unstructured":"Scott A, Wong P, Melstrom LG. Surgery and hepatic artery infusion therapy for intrahepatic cholangiocarcinoma. Surgery. 2023;174(1):113\u20135. https:\/\/doi.org\/10.1016\/j.surg.2023.01.019.","journal-title":"Surgery"},{"issue":"2","key":"4188_CR100","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s00330-021-08216-x","volume":"32","author":"GH Kim","year":"2022","unstructured":"Kim GH, Kim PH, Kim JH, Kim PN, Won HJ, Shin YM, et al. Thermal ablation in the treatment of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Eur Radiol. 2022;32(2):1205\u201315. https:\/\/doi.org\/10.1007\/s00330-021-08216-x.","journal-title":"Eur Radiol"},{"key":"4188_CR101","doi-asserted-by":"publisher","first-page":"102336","DOI":"10.1016\/j.eclinm.2023.102336","volume":"67","author":"C Pang","year":"2024","unstructured":"Pang C, Li J, Dou J, Li Z, Li L, Li K, et al. Microwave ablation versus liver resection for primary intrahepatic cholangiocarcinoma within Milan criteria: a long-term multicenter cohort study. EClinicalMedicine. 2024;67:102336. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102336.","journal-title":"EClinicalMedicine"},{"issue":"11","key":"4188_CR102","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1245\/s10434-013-3035-1","volume":"20","author":"SJ Zhang","year":"2013","unstructured":"Zhang SJ, Hu P, Wang N, Shen Q, Sun AX, Kuang M, et al. Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2013;20(11):3596\u2013602. https:\/\/doi.org\/10.1245\/s10434-013-3035-1.","journal-title":"Ann Surg Oncol"},{"key":"4188_CR103","doi-asserted-by":"publisher","first-page":"102258","DOI":"10.1016\/j.ctrv.2021.102258","volume":"99","author":"J Edeline","year":"2021","unstructured":"Edeline J, Lamarca A, McNamara MG, Jacobs T, Hubner RA, Palmer D, et al. Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. Cancer Treat Rev. 2021;99:102258. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102258.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"4188_CR104","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1200\/JCO.2015.61.3778","volume":"34","author":"R Tao","year":"2016","unstructured":"Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: A retrospective dose response analysis. J Clin Oncol. 2016;34(3):219\u201326. https:\/\/doi.org\/10.1200\/JCO.2015.61.3778.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4188_CR105","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.2015.64.2710","volume":"34","author":"TS Hong","year":"2016","unstructured":"Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, et al. Multi-Institutional phase II study of High-Dose hypofractionated proton beam therapy in patients with Localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2016;34(5):460\u20138. https:\/\/doi.org\/10.1200\/JCO.2015.64.2710.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4188_CR106","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3857\/roj.2014.32.3.163","volume":"32","author":"DH Jung","year":"2014","unstructured":"Jung DH, Kim MS, Cho CK, Yoo HJ, Jang WI, Seo YS, et al. Outcomes of stereotactic body radiotherapy for unresectable primary or recurrent cholangiocarcinoma. Radiat Oncol J. 2014;32(3):163\u20139. https:\/\/doi.org\/10.3857\/roj.2014.32.3.163.","journal-title":"Radiat Oncol J"},{"issue":"14","key":"4188_CR107","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381. https:\/\/doi.org\/10.1056\/NEJMoa0908721.","journal-title":"N Engl J Med"},{"issue":"8","key":"4188_CR108","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015.","journal-title":"NEJM Evid"},{"issue":"10391","key":"4188_CR109","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4.","journal-title":"Lancet"},{"issue":"12","key":"4188_CR110","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C Morizane","year":"2019","unstructured":"Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019;30(12):1950\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdz402.","journal-title":"Ann Oncol"},{"issue":"1","key":"4188_CR111","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jhbp.1219","volume":"30","author":"T Ioka","year":"2023","unstructured":"Ioka T, Kanai M, Kobayashi S, Sakai D, Eguchi H, Baba H, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci. 2023;30(1):102\u201310. https:\/\/doi.org\/10.1002\/jhbp.1219.","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"6","key":"4188_CR112","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","volume":"5","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, et al. Gemcitabine, Cisplatin, and nab-Paclitaxel for the treatment of advanced biliary tract cancers: A phase 2 clinical trial. JAMA Oncol. 2019;5(6):824\u201330. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0270.","journal-title":"JAMA Oncol"},{"issue":"5","key":"4188_CR113","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/annonc\/mdz058","volume":"30","author":"ST Kim","year":"2019","unstructured":"Kim ST, Kang JH, Lee J, Lee HW, Oh SY, Jang JS, et al. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Ann Oncol. 2019;30(5):788\u201395. https:\/\/doi.org\/10.1093\/annonc\/mdz058.","journal-title":"Ann Oncol"},{"issue":"10","key":"4188_CR114","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","volume":"6","author":"M Javle","year":"2021","unstructured":"Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021;6(10):803\u201315. https:\/\/doi.org\/10.1016\/S2468-1253(21)00196-5.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"4188_CR115","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncol. 2020;21(2):271\u201382. https:\/\/doi.org\/10.1016\/S1470-2045(19)30691-6.","journal-title":"Lancet Oncol"},{"issue":"8","key":"4188_CR116","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.33013","volume":"147","author":"SA Piha-Paul","year":"2020","unstructured":"Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020;147(8):2190\u20138. https:\/\/doi.org\/10.1002\/ijc.33013.","journal-title":"Int J Cancer"},{"issue":"4","key":"4188_CR117","doi-asserted-by":"publisher","first-page":"414","DOI":"10.21037\/hbsn-20-338","volume":"9","author":"J Lin","year":"2020","unstructured":"Lin J, Yang X, Long J, Zhao S, Mao J, Wang D, et al. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surg Nutr. 2020;9(4):414\u201324. https:\/\/doi.org\/10.21037\/hbsn-20-338.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"5","key":"4188_CR118","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22(5):690\u2013701. https:\/\/doi.org\/10.1016\/S1470-2045(21)00027-9.","journal-title":"Lancet Oncol"},{"issue":"11","key":"4188_CR119","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S1470-2045(21)00486-1","volume":"22","author":"C Yoo","year":"2021","unstructured":"Yoo C, Kim KP, Jeong JH, Kim I, Kang MJ, Cheon J, et al. Liposomal Irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol. 2021;22(11):1560\u201372. https:\/\/doi.org\/10.1016\/S1470-2045(21)00486-1.","journal-title":"Lancet Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04188-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04188-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04188-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:23:27Z","timestamp":1770837807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-025-04188-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":119,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4188"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04188-0","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article is a narrative review and does not involve human participants, animals, or patient data","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}